Skip to main content

Table 1 Study characteristics

From: Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis

Author, year Type of study ARB used Type of population Duration of study Number of patients Doses, mg
ARB HCTZ + ARB CTDN + ARB ARB HCTZ + ARB CTDN + ARB
Fogari et al., 2010 [20] Randomized, double-blind, parallel-group, up-titration, multicenter, multinational, phase III Olmesartan Moderate to severe hypertension, male or female patients, mean age 55.6 16 weeks 285 556   40 40/12.5, 40/25  
Benz et al., 1998 [21] Randomized, double-blind, multiple dose, placebo controlled, multifactorial, parallel Valsartan Uncomplicated essential hypertension, male or female patients, mean age 52 (22-86) 8 weeks 198 (99, 99) 379 (96, 92, 97, 94)   80, 160 80/12.5, 80/25, 160/12.5, 160/25  
Edes, 2009 [22] Randomized, double-blind, parallel-group study Candesartan Mild to moderate primary hypertension, male or female patients, mean age 53 8 weeks, 4 weeks follow-up 465 492   32 32/25  
Kwon et al., 2013 [23] Open-label, randomized, prospective cross-over study Candesartan Never treated primary hypertension, male or female patients, mean age 50 8 weeks 25 (4 weeks) 15 13 8 8/25 8/12.5
Lacourciere and Martin, 2002 [24] Prospective, randomized, double-blind, parallel-group study Telmisartan Mild-to-moderate essential hypertension, male or female patients, mean age 54.1 (28-79) 8 weeks 167 160   40 40/12.5  
Lacourciere et al., 2001 [25] Multicenter, prospective, randomized, double-blind, parallel-group study Telmisartan Mild-to-moderate, essential hypertension and inadequate BP control, male or female patients, mean age 55.6 (20-79) 8 weeks 245 246   80 80/12.5  
Lacourciere et al., 2005 [26] Randomized, double blind, 3-arm, parallel group study Valsartan Stage 2 or 3 systolic hypertension (SBP ≥ 160 mmHg and ≤ 200 mmHg) with or without other CV risk factors, male or female patients, mean age 60.8 8 weeks 261 513 (258, 255)   80, 160 160/12.5, 160/25  
Makita et al., 2009 [27] Randomized, parallel-group study Candesartan/valsartan vs telmisartan Hypertensive outpatients treated with an ARB, candesartan or valsartan, male or female patients, mean age 69.3 12 weeks 32 32   8 or 80 40/12.5  
Rhee et al., 2015 [28] Multicenter, randomized, active-controlled, double-blind, parallel-group, dose-titration trial Fimasartan Mild to moderate primary hypertension, male or female patients, mean age 55.3 8 weeks 88 175   60 60/12.5  
Sachse et al., 2002 [29] Multicenter, prospective, randomized, double-blind, parallel group study Eprosartan Mild to moderate primary hypertension, male or female patients
mean age 58.7
8 weeks, 4 weeks follow-up 157 152   600 600/12.5  
MacKay et al., 1996 [32] Multicenter, randomized, double-blind, parallel-group study Losartan Essential hypertension, male or female patients, mean age 55 (22-79) 8 weeks, 4 weeks follow-up 122 125, 114   50 50/6.25, 50/12.5  
Sica et al., 2012 [33] Phase 3, randomized, double-blind, factorial study Azilsartan Mild to moderate primary hypertension, male or female patients, mean age 57 8 weeks 470 (155, 153, 162)   928 (156, 147, 153, 154, 156, 162) 20, 40, 80   20/12.5, 40/12.5, 80/12.5, 20/25, 40/25, 80/25
Cushman et al., 2012 [34] Randomized, double-blind, forced-titration study Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide Primary hypertension, male or female patients, mean age 57 12 weeks   364 355, 352   40/25 40/25, 80/25
Cushman et al., 2018 [35] Randomized, double-blind, parallel-group study Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide Primary hypertension, male or female patients, mean age 57 8 weeks   356 372, 357   40/25 40/25, 80/25
Neutel et al., 2017 [36] Phase 3, randomized, parallel-group, open-label, multicenter, multinational study Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide Stage 2 essential hypertension, male or female patients, mean age 58.5 (> 45) 52 weeks   419 418   40/25 80/25
  1. Note: Mild to moderate hypertension stands for stage I and stage II hypertension according to “2017 High Blood Pressure Clinical Practice Guideline”
  2. Normal: Systolic < 120 and diastolic < 80 mmHg
  3. Elevated: Systolic between 120 and 129 and diastolic < 80
  4. Stage 1: Systolic between 130 and 139 or diastolic between 80 and 89
  5. Stage 2: Systolic ≥ 140 or diastolic ≥ 90 mmHg